Abstract
In the present study, the in vitro susceptibility and capsular width from both melanized and non-melanized Cryptococcus neoformans cells in the presence of Pimenta pseudocaryophyllus crude extract were determined. The results were compared with those obtained for voriconazole and amphotericin B. Melanization was obtained in minimal medium broth with the addition of L-dopa, and the antifungal susceptibility tests were performed using the broth microdilution method. Capsular width of 30 cells of each one of the isolates in medium with crude extracts of P. pseudocaryophyllus or voriconazole or amphotericin B at a concentration corresponding to 0.5 times the minimal inhibitory concentration (MIC) was measured, and the mean was calculated. The MICs and minimal fungicidal concentrations (MFCs) for plant extract and voriconazole were identical for both melanized and non-melanized C. neoformans isolates, but for amphotericin, the MFCs for melanized cells were up to 8 times higher than for non-melanized cells. The capsular width of C. neoformans cells was smaller (p < 0.001) in the presence crude extract of P. pseudocaryophyllus and of voriconazole regardless melanization. The findings of capsule alterations of C. neoformans verified in this study provide fertile ways for future research into the effects of antifungal agents on the pathogenesis of cryptococcosis.
Similar content being viewed by others
References
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–30.
Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York city. Clin Infect Dis. 1994;19:1029–33.
Ministério da Saúde do Brasil—Dados e pesquisa em DST e AIDS. Coordenação do programa nacional de DTS/AIDS Brasília; 2002. www.aids.gov.br/.
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Refocusing on a re-emergent disease: the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. In: The 48th annual ICAAC/IDSA 46th annual meeting, ASM, Washington, DC; 2008.
Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol. 2009;68:133–216.
Ngamskulrungroj P, Meyer W. Melanin production at 37 °C is linked to the high virulent Cryptococcus gattii Vancouver Island outbreak genotype VGIIa. Australas Mycol. 2009;28:9–14.
Rosas AL, Casadevall A. Melanization decreases the susceptibility of Cryptococcus neoformans to enzymatic degradation. Mycopathol. 2001;151:53–6.
Ikeda R, Sugita T, Jacobson ES. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol. 2003;47:271–7.
van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of Voriconazole on Cryptococcus neoformans. Antimicrob Agents Chem. 2004;48:2014–20.
Custódio DL, Burgo RP, Moriel B, Barbosa AM, Rezende MI, Daniel JFS, Pinto JP, Bianchini E, Faria TJ. Antimicrobial activity of essential oils from Pimenta pseudocaryophyllus and Tynanthus micranthus. Braz Arch Biol Technol. 2010;53:1363–9.
Paula JAM, Paula JR, Bara MTF, Rezende MH, Ferreira HD. Estudo farmacognóstico das folhas de Pimenta pseudocaryophyllus (Gomes) L. R. Landrum—Myrtaceae. Rev Bras Farmacogn. 2008;18:265–78.
Meyer W, Marszewska K, Amirmostofian M, Igreja RP, Hardtke C, Methling K, Viviani MA, Chindamporn A, Sukroongreung S, John MA, Ellis DH, Sorrell TC. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA—a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis. 1999;20:1790–9.
van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibility to amphotericin B and caspofungin. Antimicrob Agents Chemother. 2002;46:3394–400.
CLSI, Clinical Laboratory Standard Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standards, 3rd edn. CLSI document M27-A3, Wayne; 2008.
Rodriguez-Tudela JL, Cuenca-Estrella M, Diaz-Guerra TM, Mellado E. Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol. 2001;39:2513–7.
Torres-Rodriguez JM, Alvarado-Ramirez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii. J Antimicrob Chemother. 2008;62:205–10.
Zaragoza O, Casadevall A. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online. 2004;6:10–5.
Mednick AJ, Nosanchuk JD, Casadevall A. Melanization of Cryptococcus neoformans affects lung inflammatory responses during cryptococcal infection. Infect Immun. 2005;73:2012–9.
Passos XS, Castro AC, Pires JS, Garcia ACF, Campos FC, Fernandes OFL, Paula JR, Ferreira HD, Santos SC, Ferri PH, Silva MRR. Composition and antifungal activity of the essential oils of Caryocar brasiliensis. Pharm Biol. 2003;41:219–24.
Lemos JA, Passos XS, Fernandes OFL, Paula JR, Ferri PH, Souza LKH, Lemos AA, Silva MRR. Antifungal activity from Ocimum gratissimum L. Towards Cryptococcus neoformans. Mem Inst Oswaldo Cruz. 2005;100:55–8.
Souza ACM, Kato L, Silva CC, Cidade AF, Oliveira CMA, Silva MRR. Antimicrobial activity of Hymenaea martiana towards dermatophytes and Cryptococcus neoformans. Mycoses. 2010;53:500–3.
Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microb Rev. 1999;12:501–17.
Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis. 2005;41:521–6.
Scorzoni L, Benaducci T, Almeida AMF, Silva DHS, Bolzani VS, Gianinni MJM. The use of standard methodology for determination of antifungal activity of natural products against medical yeasts Candida sp. and Cryptococcus sp. Braz J Microbiol. 2007;38:391–7.
Paula JAM. Fitoquímica e atividades biológicas de Pimenta pseudocaryophyllus (Gomes) L. R. Landrum (Myrtaceae), Tese de Doutorado, Goiânia: Universidade Federal de Goiás; 2011. p. 204.
Paula JAM, Reis JB, Ferreira LHM, Menezes AS, Paula JR. Revisão Gênero Pimenta: aspectos botânicos, composição química e potencial farmacológico. Rev Bras Plantas Med Botucatu. 2010;12:363–79.
Paula JAM, Paula JR, Pimenta FC, Rezende MH, Bara MTF. Antimicrobial activity of the crude ethanol extract from Pimenta pseudocaryophyllus. Pharm Biol. 2009;47:987–93.
Ghannoun MA, Spellberg B, Ibrahim AS, Ritchie JA, Currie B, Spitzer ED, Edwards JE Jr, Casadevall A. Sterol Composition of Cryptococcus neoformans in the presence and absence of Fluconazole. Antimicrob Agents Chemother. 1994;38:2029–33.
Doering TL. How sweet it is! Capsule formation and cell wall biogenesis in Cryptococcus neoformans. Annu Rev Microbiol. 2009;63:223–47.
Martinez LR, Moussai D, Casadevall A. Antibody to Cryptococcus neoformans Glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun. 2004;72:3674–9.
Acknowledgments
We thank Pfizer for supplying Voriconazole powder.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Fátima Lisboa Fernandes, O., Costa, C.R., de Souza Lino Junior, R. et al. Effects of Pimenta pseudocaryophyllus (Gomes) L. R. Landrum, on Melanized and Non-melanized Cryptococcus neoformans . Mycopathologia 174, 421–428 (2012). https://doi.org/10.1007/s11046-012-9574-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11046-012-9574-3